IP Library › Granted Patent US 12,396,924
Granted Patent B2
US 12,396,924 · App. 18/393,974 · Granted Aug 26, 2025

Adapter for use in a planetary mixer

Inventor: Panagiota Danopoulos (St-Laurent, CA)
Assignee: MEDISCA PHARMACEUTIQUE INC.
A61J1/05A61J3/04A61K9/0034A61K9/06A61K9/107A61K31/045A61K31/135A61K31/137A61K31/192A61K31/195A61K31/196A61K31/197A61K31/351A61K31/4418A61K31/4422A61K31/445A61K31/4458A61K31/565A61K31/57A61K31/7048A61K33/14A61K47/10A61K47/26A61K47/38A61K47/42A61K47/46B01F29/10B01F29/32B01F29/40B01F29/401B01F29/4011B01F29/40221B01F31/00B01F35/2209B01F35/421B29B7/106B65B7/16B01F29/40365
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,396,924
App. No.
18/393,974
Granted
Aug 26, 2025
Kind
B2
Abstract

A dispensing container and adapter system for use with a planetary mixer is disclosed. The dispensing container has a longitudinal axis and a transverse axis. The dispensing container may include a nozzle and a removable cap to cover the nozzle. The removable cap may have a first width dimension measured along the transverse axis. The dispensing container may include a body having a second width dimension measured along the transverse axis. An adapter may receive the dispensing container. The adapter may include a cavity to receive the removable cap. The cavity may have a cavity width that exceeds the first width dimension. The adapter may also include a recess for receiving a portion of the dispensing container. The recess may extend from the cavity. At least a portion of the recess may have a width dimension smaller than both the first width dimension and the second width dimension.

Claims (25)

1. A method, comprising:

subjecting a container, that includes an edible material in a solid state therein, to superimposed revolution and rotation movements in a bladeless planetary mixer, wherein the superimposed revolution and rotation movements are sufficient to raise the temperature of the edible material to between 55° C. and 72° C. to melt the edible material without adding external heat to obtain a pourable edible material, wherein the edible material includes gelatin and can be reversibly melted; and

cooling the pourable edible material to obtain a solid edible composition.

2. The method of claim 1 , wherein the superimposed revolution and rotation movements are configured to cause an elevation in temperature of the edible material by at least 25 degrees Celsius and not more than 35 degrees Celsius.

3. The method of claim 1 , wherein the superimposed revolution and rotation movements are configured to cause the elevation in temperature of the edible material by at least 35 degrees Celsius and not more than 40 degrees Celsius.

4. The method of claim 1 , wherein the superimposed revolution and rotation movement are configured to cause the elevation in temperature of the edible material by at least 40 degrees Celsius and not more than 48 degrees Celsius.

5. The method of claim 1 , further comprising adding an active pharmaceutical ingredient (API) to the container containing the edible material in the solid state prior to subjecting the container to the superimposed revolution and rotation movements in the bladeless planetary mixer.

6. The method of claim 1 , wherein the superimposed revolution and rotation movements are first superimposed revolution and rotation movements, the method further comprising adding an active pharmaceutical ingredient (API) to the container containing the melted edible material and subjecting the container to second superimposed revolution and rotation movements to mix the API with the pourable edible material before cooling the edible material to obtain the solid edible composition.

7. The method of claim 1 , wherein cooling the edible pourable material includes cooling in a mold having a desired shape.

8. The method of claim 1 , wherein the superimposed revolution and rotation movements are maintained for a period of time of at least 180 seconds.

9. The method of claim 1 , wherein the superimposed revolution and rotation movements are maintained for a period of time of at least 300 seconds.

10. The method of claim 1 , wherein the superimposed revolution and rotation movements generate a G force on the edible material of at least 180 G.

11. The method of claim 1 , wherein the superimposed revolution and rotation movements generate a G force on the edible material of at least 200 G.

12. The method of claim 1 , wherein the superimposed revolution and rotation movements generate a G force on the edible material of at least 250 G.

13. The method of claim 5 , wherein the API includes a dietary supplement.

14. The method of claim 5 , wherein the API includes a nutritional agent.

15. A method, comprising:

subjecting a container, that includes an edible material in a solid state therein, to first superimposed revolution and rotation movements in a bladeless planetary mixer, wherein the superimposed revolution and rotation movements are sufficient to melt the edible material without the addition of external heat to obtain a pourable edible material, wherein the edible material includes gelatin and can be reversibly melted, and wherein the superimposed revolution and rotation movements are configured to cause an elevation in temperature of the edible material by at least 31 degrees Celsius and not more than 48 degrees Celsius; and

cooling the edible pourable material to obtain a solid edible composition.

16. The method of claim 15 , wherein the superimposed revolution and rotation movements are first superimposed revolution and rotation movements, the method further comprising adding an active pharmaceutical ingredient (API) to the container containing the melted edible material and subjecting the container to second superimposed revolution and rotation movements to mix the API with the pourable edible material, before cooling the edible material to obtain the solid edible composition.

17. The method of claim 15 , wherein the superimposed revolution and rotation movements are maintained for a period of time of at least 180 seconds.

18. A method, comprising:

subjecting a container, that includes an edible material in a solid state therein, to superimposed revolution and rotation movements in a bladeless planetary mixer, wherein the edible material includes gelatin and can be reversibly melted, wherein the superimposed revolution and rotation movements are sufficient to raise the temperature of the edible material to between 55° C. and 72° C. to melt the edible material without the addition of external heat to obtain a pourable edible material, and wherein the superimposed revolution and rotation movements are maintained for a period of time of at least 180 seconds; and

cooling the edible pourable material to obtain a solid, semi-solid or chewable edible composition.

19. The method of claim 18 , wherein the superimposed revolution and rotation movements are first superimposed revolution and rotation movements, the method further comprising adding an active pharmaceutical ingredient (API) to the container containing the melted edible material and subjecting the container to second superimposed revolution and rotation movements to mix the API with the pourable edible material.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2023
From: DANOPOULOS, PANAGIOTA
To: MEDISCA PHARMACEUTIQUE INC.
Reel/Frame 065940/0905 →
Continuity (6)
Continuation 17123442 · Dec 16, 2020
Continuation 16372006 · Apr 1, 2019
Continuation 16131986 · Sep 14, 2018
Continuation 15809636 · Nov 10, 2017
Provisional Application 62420426 · Nov 10, 2016
Related Publication 20240148608A1 · May 9, 2024
References Cited (260)
US 947922A · Lewis · 1910 [cited by applicant]
US 1059947A · McHenry · 1913 [cited by applicant]
US 1101351A · Suit · 1914 [cited by applicant]
US 1998692A · Rossem et al. · 1935 [cited by applicant]
US 2728494A · Hobson · 1955 [cited by applicant]
US 3029187A · Steinhardt et al. · 1962 [cited by applicant]
US 3164303A · Trautmann · 1965 [cited by applicant]
US 3470927A · Craig · 1969 [cited by applicant]
US 3778033A · Pullman · 1973 [cited by applicant]
US 4114803A · Romanuauskas · 1978 [cited by applicant]
US 4323492A · Zimmermann et al. · 1982 [cited by applicant]
US 4483847A · Augart · 1984 [cited by applicant]
US 4497581A · Miller · 1985 [cited by applicant]
US 4900159A · Jamison · 1990 [cited by applicant]
US 4966468A · Brüning · 1990 [cited by applicant]
US 5238304A · Zimmermann · 1993 [cited by applicant]
US 6099160A · Flackett · 2000 [cited by applicant]
US 6634576B2 · Verhoff et al. · 2003 [cited by applicant]
US 6755565B2 · Flackett · 2004 [cited by applicant]
US 7213994B2 · Phipps et al. · 2007 [cited by applicant]
US 7438460B2 · Schmidt et al. · 2008 [cited by applicant]
US 7748892B2 · McCoy · 2010 [cited by applicant]
US 8191729B2 · Deusser et al. · 2012 [cited by applicant]
US 8360629B2 · Globerman et al. · 2013 [cited by applicant]
US 8388984B2 · Huguet et al. · 2013 [cited by applicant]
US 8408418B2 · Kuzelka · 2013 [cited by applicant]
US 8845180B2 · Huckby · 2014 [cited by applicant]
US 8932417B1 · Renz et al. · 2015 [cited by applicant]
US 8945606B2 · Haley · 2015 [cited by applicant]
US 8950929B2 · Globerman et al. · 2015 [cited by applicant]
US 9043019B2 · Eliuk et al. · 2015 [cited by applicant]
US 9259696B2 · Globerman et al. · 2016 [cited by applicant]
US 9770697B2 · Denize et al. · 2017 [cited by applicant]
US 10231903B2 · Danopoulos et al. · 2019 [cited by applicant]
US 10420705B2 · Danopoulos et al. · 2019 [cited by applicant]
US 10494164B2 · Nickerson et al. · 2019 [cited by applicant]
US 10631906B2 · Globerman et al. · 2020 [cited by applicant]
US 10765600B2 · Danopoulos et al. · 2020 [cited by applicant]
US 10766047B2 · Wong et al. · 2020 [cited by applicant]
US 10874489B2 · Pierson et al. · 2020 [cited by applicant]
US 10993876B2 · Danopoulos et al. · 2021 [cited by applicant]
US 11090224B2 · Danopoulos et al. · 2021 [cited by applicant]
US 11096864B2 · Danopoulos et al. · 2021 [cited by applicant]
US 20010019725A1 · Miller et al. · 2001 [cited by applicant]
US 20020012701A1 · Kolter et al. · 2002 [cited by applicant]
US 20020136089A1 · Folestad et al. · 2002 [cited by applicant]
US 20030142583A1 · Santospago et al. · 2003 [cited by applicant]
US 20030179646A1 · Miller · 2003 [cited by applicant]
US 20030198126A1 · Flackett · 2003 [cited by applicant]
US 20040211747A1 · Whitley · 2004 [cited by applicant]
US 20040265344A1 · Zolotariov · 2004 [cited by applicant]
US 20060105022A1 · Yokokawa et al. · 2006 [cited by applicant]
US 20060108318A1 · Chisholm · 2006 [cited by applicant]
US 20060175443A1 · Bysouth · 2006 [cited by applicant]
US 20070002680A1 · Vanderbilt et al. · 2007 [cited by applicant]
US 20070002681A1 · Vanderbilt · 2007 [cited by applicant]
US 20070002682A1 · Vanderbilt et al. · 2007 [cited by applicant]
US 20070025180A1 · Ishii · 2007 [cited by applicant]
US 20070140049A1 · Johnson et al. · 2007 [cited by applicant]
US 20070280038A1 · Schmidt et al. · 2007 [cited by applicant]
US 20080212405A1 · Globerman et al. · 2008 [cited by applicant]
US 20090040865A1 · Benjamin, II · 2009 [cited by applicant]
US 20090163860A1 · Patrick et al. · 2009 [cited by applicant]
US 20090196119A1 · Greco et al. · 2009 [cited by applicant]
US 20100161113A1 · Tribble et al. · 2010 [cited by applicant]
US 20100185322A1 · Bylsma et al. · 2010 [cited by applicant]
US 20100265791A1 · Ishii · 2010 [cited by applicant]
US 20120135047A1 · Dodd et al. · 2012 [cited by applicant]
US 20120135846A1 · Yao et al. · 2012 [cited by applicant]
US 20120269029A1 · Konietzko et al. · 2012 [cited by applicant]
US 20120307586A1 · Globerman et al. · 2012 [cited by applicant]
US 20130121105A1 · Denize et al. · 2013 [cited by applicant]
US 20130261188A1 · Hibi et al. · 2013 [cited by applicant]
US 20150336712A1 · Taheri · 2015 [cited by applicant]
US 20160045876A1 · Kaucky et al. · 2016 [cited by applicant]
US 20160067178A1 · Arps et al. · 2016 [cited by applicant]
US 20160235459A1 · Globerman et al. · 2016 [cited by applicant]
US 20160251121A1 · Hadar et al. · 2016 [cited by applicant]
US 20160262421A1 · Biglari et al. · 2016 [cited by applicant]
US 20180125753A1 · Danopoulos et al. · 2018 [cited by applicant]
US 20180345305A1 · Wong et al. · 2018 [cited by applicant]
US 20180353919A1 · LaRose · 2018 [cited by applicant]
US 20190008723A1 · Danopoulos et al. · 2019 [cited by applicant]
US 20190224073A1 · Danopoulos et al. · 2019 [cited by applicant]
US 20200054522A1 · Danopoulos et al. · 2020 [cited by applicant]
US 20200345581A1 · Danopoulos et al. · 2020 [cited by applicant]
US 20200345582A1 · Danopoulos et al. · 2020 [cited by applicant]
US 20210086150A1 · Danopoulos et al. · 2021 [cited by applicant]
US 20240108543A1 · Danopoulos · 2024 [cited by examiner]
BR 112019009594 · 2019 [cited by applicant]
CA 1246053A · 1988 [cited by applicant]
CA 2352874A1 · 2006 [cited by applicant]
CA 3062126C · 2018 [cited by applicant]
CN 203107245U · 2013 [cited by applicant]
DE 4216252A1 · 1993 [cited by applicant]
DE 19855440A1 · 2000 [cited by applicant]
DE 102006049347A1 · 2008 [cited by applicant]
DE 102008039745A1 · 2009 [cited by applicant]
DE 10066151B4 · 2010 [cited by applicant]
DE 102010060650A1 · 2011 [cited by applicant]
DE 102012105819A1 · 2014 [cited by applicant]
DE 102015100006A1 · 2016 [cited by applicant]
DE 202017007678U1 · 2024 [cited by applicant]
EP 0599783B1 · 1998 [cited by applicant]
EP 1559438 · 2005 [cited by applicant]
EP 2033707A1 · 2009 [cited by applicant]
EP 2581123A1 · 2013 [cited by applicant]
EP 3538071B1 · 2022 [cited by applicant]
EP 4151306A1 · 2023 [cited by applicant]
ES 2317611T3 · 2009 [cited by applicant]
JP S63291635A · 1988 [cited by applicant]
JP H11226376A · 1999 [cited by applicant]
JP 2001347152A · 2001 [cited by applicant]
JP 2002320835 · 2002 [cited by applicant]
JP 2006175349A · 2006 [cited by applicant]
JP 2006289163A · 2006 [cited by applicant]
JP 2006305512 · 2006 [cited by applicant]
JP 3977918B2 · 2007 [cited by applicant]
JP 2008531572A · 2008 [cited by applicant]
JP 2009208026 · 2009 [cited by applicant]
JP 2010194470A · 2010 [cited by applicant]
JP 2013237038A · 2013 [cited by applicant]
JP 2013237041A · 2013 [cited by applicant]
JP 2014065010A · 2014 [cited by applicant]
JP 2015500334A · 2015 [cited by applicant]
JP 2015027676A · 2015 [cited by applicant]
JP 2015092148A · 2015 [cited by applicant]
JP 2016523950A · 2016 [cited by applicant]
JP 2019535708A · 2019 [cited by examiner]
WO 9702089 · 1997 [cited by applicant]
WO 2003089124A1 · 2003 [cited by applicant]
WO 2006042091A1 · 2006 [cited by applicant]
WO 2009020167A1 · 2009 [cited by applicant]
WO 2012133492A1 · 2012 [cited by applicant]
WO 2014083029A1 · 2014 [cited by applicant]
WO 2014144814A1 · 2014 [cited by applicant]
WO 2015160358A1 · 2015 [cited by applicant]
WO 2018085942A1 · 2018 [cited by applicant]
Chemical Book, Lactose CAS# 63-42-3, obtained online at https://www.chemicalbook.com/ProductChemicalPropertiesCB8710411_EN.htm, downloaded on Apr. 17, 2024. (Year: 2024). [cited by examiner]
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Central Nervous System (CNS) Stimulants. [Upda… [cited by examiner]
Chemical Book, 112111-43-0(armodafinil), obtained online at https://www.chemicalbook.com/ChemicalProductProperty_US_CB3500844.aspx, downloaded on Apr. 17, 2024. (Year: 2024). [cited by examiner]
Allen, Loyd V., and M. A. Erickson. “Secundum Artem.” Current and Practical Compounding Information for the Pharmacist Pharmaceutical Compounding Resources on the Internet 10.1. (Year: 2009). [cited by examiner]
Nichols, 6.1C: Melting Point Theory, obtained online at: https://chem.libretexts.org/@go/page/93433, downloaded on Jul. 28, 2024. (Year: 2022). [cited by examiner]
PPHhealthcare, Understanding the Temperature-Sensitive Nature of Drugs, obtained online at: https://pphealthcaresolutions.co.uk/understanding-temperature-sensitive-drugs/#:˜:text=Thermolabile%20drugs%20are%20those%20tha… [cited by examiner]
World Health Organization. Temperature sensitivity of vaccines. No. WHO/IVB/06.10. World Health Organization, 2006. (Year: 2006). [cited by examiner]
Christchurch Medicines Information Service, Assessing medicines when stored outside manufacturer recommendations, obtained online at: https://www.medicinesinformation.co.nz/bulletins/assessing-medicines-when-stored-outs… [cited by examiner]
Crichton, Brian. “Keep in a cool place: exposure of medicines to high temperatures in general practice during a British heatwave.” Journal of the royal society of medicine 97.7 (2004): 328-329. (Year: 2004). [cited by examiner]
Notice of Allowance issued on Jan. 21, 2021, in connection with U.S. Appl. No. 16/372,006, 18 pages. [cited by applicant]
Notice of Allowance issued on Jun. 7, 2021, in connection with U.S. Appl. No. 16/932,313, 7 pages. [cited by applicant]
Notice of Allowance issued on May 13, 2021, in connection with U.S. Appl. No. 16/932,171, 5 pages. [cited by applicant]
Office Action issued on Feb. 24, 2021, in connection with European Patent Application No. 17868979.0, 6 pages. [cited by applicant]
Office Action issued on Jun. 2, 2021, in connection with U.S. Appl. No. 17/123,400, 16 pages. [cited by applicant]
Office Action issued on Mar. 29, 2021, in connection with U.S. Appl. No. 16/932,171, 7 pages. [cited by applicant]
Office Action issued on Mar. 4, 2021, in connection with U.S. Appl. No. 16/932,313, 21 pages. [cited by applicant]
Office Action issued on Mar. 9, 2021, in connection with U.S. Appl. No. 16/932,171, 12 pages. [cited by applicant]
Restriction Requirement issued on May 12, 2021, issued in connection with U.S. Appl. No. 17/123,400, 5 pages. [cited by applicant]
Examiner's report issued on Jul. 22, 2021, in connection with Canadian Patent Application No. 3,106,928, 3 pages. [cited by applicant]
Examiner's Report issued on Nov. 4, 2021, in connection with CA patent application No. 3,131,133—5 pages. [cited by applicant]
Examiner's Report issued on Nov. 9, 2021, in connection with CA patent application No. 3,106,934—6 pages. [cited by applicant]
Examiner's Report issued Dec. 2, 2021, in connection with CA patent application No. 3,131,129—6 pages. [cited by applicant]
Office Action issued Oct. 12, 2021, in connection with Japanese patent application No. 2019-524437—6 pages (+ English translation, 8 pages). [cited by applicant]
Final Office Action issued on Dec. 10, 2021, in connection with U.S. Appl. No. 17/123,400 (7 pages). [cited by applicant]
Communication under Rule 71(3) EPC issued Apr. 5, 2022, in connection with EP patent application No. 17 868 979.0 (7 pages). [cited by applicant]
Notice of Allowance issued Apr. 7, 2022, in connection with CA patent application No. 3,106,928 (1 page). [cited by applicant]
Examiner's Report issued May 3, 2022, in connection with CA patent application 3131129 (4 pages). [cited by applicant]
Notice of Allowance issued Apr. 27, 2022, in connection with CA patent application 3043494 (1 page). [cited by applicant]
Examiner's Report issued May 4, 2022, in connection with CA patent application 3131133 (4 pages). [cited by applicant]
A Novel Blending Method for Dispensing Powdered Medicine—Chem Pharm Bull 62(1) 54-57 (2014)—(4 pages). [cited by applicant]
Kitagawa, S. et al.; Effects of Mixing Procedure Itself on the Structure, Viscosity, and Spreadability of White Petrolatum and Salicylic Acid Ointment and the Skin Permeation of Salicylic Acid; Chem. Pharm. Bull. vol. 6… [cited by applicant]
20 Ways Improving Patient Care & Pharmacy Profitability; Cardinal Health Community Specialty LTC; Copyright 2017 (92 pages). [cited by applicant]
The MAZ Mixing Machine-New Capabilities; YouTube video, https://www.youtube.com/watch?v=Iddugkg88EI, lists “Jan. 5, 2017”. [cited by applicant]
Download the Maz Brochure https//:web.archive.org/web/20170731081433/https://www.medisca.com/Pages/Product Details/Mazerustar/pdf/ Mazerustar Brochure for Web download.pdf, 2017. [cited by applicant]
Medisca, Mazerustar—A Revolutionary Mixer Ideal for Topicals, Liquids, Creams, and Powders, from web archive.org that lists “20170731081433” in the URL (69 pages). https//:web.archive.org/web/20170731081433/https://www.… [cited by applicant]
Medisca, Your Trusted Partner in Compounding; The Maz Mix. Deaerate. Melt. Mill.; Learn More, taken from web.archive.org that lists “20170613112836” in the URL (1 page), https//:web.archive.org/web/20170613112836/https:… [cited by applicant]
Medisca, Your Trusted Partner in Compounding;The Maz Mix. Deaerate. Melt. Mill.; Compounding Products, taken from web.archive.org that lists “20170613112836” in the URL (37 pages), https://web.archive.org/web/2017061311… [cited by applicant]
Medisca, Your Trusted Partner in Compounding; Promotions, Your Monthly Specials Are Here; View Specials, taken from web.archive.org that lists “20170603222511” in the URL (1 page), https://web.archive.org/web/2017060322… [cited by applicant]
Compounding Pharmacy Products and Services at Medisca; Medisca, Your Trusted Partner in Compounding; Promotions, Your Monthly Specials Are Here; View Specials, taken from web.archive.org that lists “20170603222511” in t… [cited by applicant]
Tian et al.; “Vesicular phospholipid gel-based depot formulations for pharmaceutical proteins: Development and in vitro evaluation”; Journal of Controlled Release 142 (2010); pp. 319-325. [cited by applicant]
Mazerustar, One Single Technology Multiple Capabilities, Apr. 12, 2017, Medisca (8 pages). [cited by applicant]
Medisca, Your Trusted Partner in Compounding: New Base (Gelatin Gum Base), Jun. 25, 2014, (1 page). [cited by applicant]
Hunnius Pharmazeutisches Worterbuch, Walter de Gruyter GmbH, Berlin/Boston, copyright 2014 (6 pages). [cited by applicant]
Expert Opinion of Prof. Dr. Gerhard Winter regarding German part of the European patent EP 3 538 071 B1, Jan. 17, 2024 (28 pages). [cited by applicant]
Rudolf Voigt, Pharmazeutische Technologie Fur Studium und Beruf, Deutscher Apotheker Verlag Stuttgart, copyright 2010 (8 pages). [cited by applicant]
Claim chart submitted in action for revocation of EP 3538071, dated Jan. 19, 2024 (3 pages). [cited by applicant]
Medisca Response to EPO Communication of Mar. 27, 2023, dated Sep. 22, 2023 (12 pages). [cited by applicant]
Medisca Response to EPO Communication of Dec. 22, 2023, dated Apr. 22, 2024 (24 pages). [cited by applicant]
EPO Summons to attend Oral Proceedings in EP 22192358.4, dated Jun. 10, 2024 (5 pages). [cited by applicant]
Oh! Planetary centrifugal mixers contribute to society, Mar. 2016 (20 pages). [cited by applicant]
Gako International Brochure, copyright 2016 (1 page). [cited by applicant]
Application for cancellation of utility model No. DE 202017007678, Jul. 10, 2024 (3 pages). [cited by applicant]
Submission regarding German utility model DE202017007678.0, dated Apr. 4, 2024 (132 pages). [cited by applicant]
Order of the District Court of Munich regarding EP 3 538 071, dated Apr. 9, 2024 (6 pages). [cited by applicant]
Martin A Erickson III, RPh, “Your Compounding Questions Answered,” Pharmacy Times, vol. 78, Issue 7 (dated Jul. 9, 2012). [cited by applicant]
Lj. Djakovic et al., “Rheological Behavior of Thixotropic Starch and Gelatin Gels,” vol. 42, No. 10, pp. 380-385 (copyright 1990). [cited by applicant]
Shilpa Sanwlani et al., “Hydration of Gelatin Molecules in Glycerol—Water Solvent and Phase Diagram of Gelatin Organogels,” J. Phys. Chem., vol. 115, pp. 7332-7340 (copyright 2011). [cited by applicant]
Fernando A. Osorio et al., “Effects of Concentration, Bloom Degree, and pH on Gelatin Melting and Gelling Temperatures Using Small Amplitude Oscillatory Rheology,” Intl. J. Food Properties, vol. 10, pp. 841-851, (copyri… [cited by applicant]
Susumu Goto et al., “Turbulent mixing in a precessing sphere,” Phys. Fluids, vol. 26, 24 pages, (copyright 2014). [cited by applicant]
Pediatric Compounding—PCCA—Professional Compounding Centers of America website at http://web.archive.org/web/20150926003212/http://www.pccarx.com/what-is-compounding/speciality-compounding/pediatric-compounding, Sep. 26… [cited by applicant]
Flavor Compounding—PCCA—Professional Compounding Centers of America website at http://web.archive.org/web/20151231124835/http://www.pccarx.com:80/what-is-compounding/speciality-compounding/flavor-compounding, Dec. 31, 2… [cited by applicant]
Francesca Milano et al., “Current Trends in Gelatin-Based Drug Delivery Systems,” Pharmaceutics, vol. 15, (copyright 2023) (34 pages). [cited by applicant]
SpeedMixer Technology—Bladeless Mixing | Speedmixer website at http://web.archive.org/web/20160128164145/http://speedmixer.com:80/speedmixer-technology, Jan. 28, 2016 (2 pages). [cited by applicant]
SpeedMixer Containers website at http://web.archive.org/web/20130119075143/http://www.speedmixer.com/containers.php, Jan. 19, 2013 (1 page). [cited by applicant]
Mixer Mill MM400 website at http://web.archive.org/web/20160115200322/http://www.retsch.com: 80/products//milling/ball-mills/mixer-mill-mm-400/function-features/, Jan. 15, 2016 (6 pages). [cited by applicant]
International Search Report issued on Feb. 6, 2018 in connection with International Patent Application No. PCT/CA2017/051350, 3 pages. [cited by applicant]
Written Opinion issued on Feb. 6, 2018 in connection with International Patent Application No. PCT/CA2017/051350, 4 pages. [cited by applicant]
Non-Final Office Action issued on Apr. 10, 2018 in connection with U.S. Appl. No. 15/809,636, 19 pages. [cited by applicant]
Non-Final Office Action issued on Dec. 10, 2018 in connection with U.S. Appl. No. 16/131,986, 18 pages. [cited by applicant]
Restriction Requirement issued on May 24, 2019 in connection with U.S. Appl. No. 16/372,006, 6 pages. [cited by applicant]
Examiner's Report issued on Jul. 25, 2019 in connection with Canadian Patent Application No. 3,043,494, 3 pages. [cited by applicant]
Non-Final Rejection issued on USPTO on Aug. 15, 2019 in connection with U.S. Appl. No. 16/372,006, 17 pages. [cited by applicant]
Non-Final Office Action issued on Dec. 9, 2019 in connection with U.S. Appl. No. 16/662,423, 15 pages. [cited by applicant]
Examiner's Report issued on Dec. 13, 2019 in connection with Canadian Patent Application No. 3,043,494, 4 pages. [cited by applicant]
Final Office Action issued on Dec. 16, 2019 in connection with U.S. Appl. No. 16/372,006, 19 pages. [cited by applicant]
Examiner's Report issued on Feb. 6, 2020 in connection with Canadian Patent Application No. 3,062,126 3 pages. [cited by applicant]
Examiner's Report issued on Feb. 12, 2020 in connection with Canadian Patent Application No. 3,043,494, 5 pages. [cited by applicant]
Advisory Action and Applicant-initiated Interview Summary issued on Mar. 26, 2020 in connection with U.S. Appl. No. 16/372,006, 9 pages. [cited by applicant]
Notice of Allowance issued on Apr. 10, 2020 in connection with U.S. Appl. No. 16/662,423, 14 pages. [cited by applicant]
Supplementary European Search Report issued on Apr. 23, 2020 in connection with European Patent Application No. 17 86 8979, 2 pages. [cited by applicant]
Extended European Search Report issued May 6, 2020 in connection with European Patent Application No. 17 86 8979, 4 pages. [cited by applicant]
Restriction Requirement issued on Aug. 7, 2020 in connection with U.S. Appl. No. 16/932,313, 7 pages. [cited by applicant]
Restriction Requirement issued on Aug. 7, 2020 in connection with U.S. Appl. No. 16/932,171, 7 pages. [cited by applicant]
Office Action issued on Aug. 12, 2020 in connection with U.S. Appl. No. 16/372,006, 25 pages. [cited by applicant]
Examiner's Report issued on Oct. 23, 2020 in connection with Canadian Patent Application No. 3062126, 3 pages. [cited by applicant]
Applicant-initiated Interview summary issued on Oct. 26, 2020 in connection with U.S. Appl. No. 16/372,006, 12 pages. [cited by applicant]
Esezobo S et al., “Moisture and gelatin effects on the interparticle attractive forces and the compression behaviour of oxytetracycline formulations” 7 pages (Year: 1977). [cited by applicant]
English translation of Suzuki et al. JP 2002-320835 (Year: 2002)). [cited by applicant]
English translation of Thinky Corp et al. (JP 2009-208026) (Year: 2009). [cited by applicant]
Karim A.A. et al., Food Hydrocolloids, 23, pp. 563-576 (Year: 2009). [cited by applicant]
Intertronics, THINKY An Introduction to Planetary Centrifugal Mixers, obtained online at: http://www.intertronics.co.uk/wp-content/uploads/2017/04/getting_to_know_thinky_mixers.pdf, pp. 1-26. (Year: 2009). [cited by applicant]
Intertronics, THINKY An introduction to Planetary Centrifugal Mixers, obtained online at https://www.intertronics.co.uk/wp-content/uploads/2017/04/getting_to_know_mixers.pdf, pp. 1-26 (Year:2011). [cited by applicant]
Ice.edu, Taste Test: Fluid Gels, obtained online at: https://www.ice.edu/blog/taste-test-fluid-gels, pp. 1-5 (Year:2012). [cited by applicant]
USP on Compounding, A Guide for the Compounding Practitioner—2014, Nov. 2013, (375 pages). [cited by applicant]
Miyazaki et al., “A novel blending method for dispensing powered medicine”, Chem. Pharm. Bull., 2014, vol. 62, Issue 1, pp. 54-57. [cited by applicant]
Keiichi, Hori “User interview—Prosessor Keiichi hori JAXA”, Thinky Library, obtained at: https://www.thinkymixer.com/en-gl/library/interview/user-interview-professor-keiichi-hori-jaxa/ Jul. 14, 2016. [cited by applicant]
Screen Captures from YouTube video clip entitled “Planetary Centrifual Mixer ARE 310” obtained at: https://www.youtube.com/watch?v=fIMHXrfWYfM, 2015. [cited by applicant]
Notice of Allowance issued on Apr. 10, 2020 in connection with United States U.S. Appl. No. 16/662,423, 16 pages. [cited by applicant]
“Pursuing a Bight Future With Mixxing Technology”; THINKY; final page of document lists Apr. 2016; (8 pages). [cited by applicant]
“Pioneering Planetary Centrifugal Mixers”; Thinky Mixer Series; final page of document lists “Oct. 2010” (32 pages). [cited by applicant]
THINKY Mixer ARE-310 Instruction Manual; “Planetary Centrifugal Mixer”; THINKY Corporation; p. 65 of document lists “Issued Nov. 7, 2008” and “Revised Aug. 18, 2010” (66 pages). [cited by applicant]
Chen et al., “Nanonization Strategies For Poorly Water-Soluble Drugs,” Drug Discovery Today, vol. 16, Nos. 7/8; Apr. 2011; 7 pages. [cited by applicant]
Food and Drug Administration; Draft “Guidance For Industry Powder Blends and Finished Dosage Units—Stratified In-Process Dosage Unit Sampling and Assessment”; Oct. 2003; 18 pages. [cited by applicant]
Hiseman et al., “Granular Flow in a Planetary Mixer,” Institution of Chemical Engineers, Trans IChemE; vol. 80, Part A, Jul. 2002, 9 pages. [cited by applicant]
Mehrotra et al., “Comparing Mixing Performance of Uniaxial and Biaxial Bin Blenders,” Powder Technology 196 (2009), 7 pages. [cited by applicant]
Niwa et al., “Novel Technology to Prepare Oral Formulations for Preclinical Safety Studies,” International Journal of Pharmaceutics 350 (2008), 9 pages. [cited by applicant]
Niwa et al., “Universal Wet-Milling Technique to Prepare Oral Nanosuspension Focused on Discovery and Preclinical Animal Studies—Development of Particle Design Method,” International Journal of Pharmaceutics 405 (2011),… [cited by applicant]
Sawant et al., “Drug Nanocrystals: Novel Technique for Delivery of Poorly Soluble Drugs,” International Journal of Science Innovations and Discoveries, vol. 1, Issue 3, Nov.-Dec. 2011, 15 pages. [cited by applicant]
Takatsuka et al., “Nanosizing of Poorly Water Soluble Compounds Using Rotation/Revolution Mixer,” Chem. Pharm. Bull. 57(10); Oct. 2009; 7 pages. [cited by applicant]
Yin, Trudy; “A Guide to Blend Uniformity,” Journal of GXP Compliance, vol. 12, No. 1, Oct. 2007, 6 pages. [cited by applicant]
Applicant-initiated Interview Summary issued on Apr. 2, 2021, in connection with U.S. Appl. No. 16/932,171, 2 pages. [cited by applicant]
Examiner Report issued on May 21, 2021, in connection with Canadian Patent Application No. 3,043,494, 3 pages. [cited by applicant]
Examiner's Report issued on Mar. 5, 2021, in connection with Canadian patent application No. 3,106,928, 4 pages. [cited by applicant]
Examiner's Report issued on Feb. 5, 2021, in connection with Canadian patent application No. 3,043,494, 4 pages. [cited by applicant]
Examiner's Report issued on May 10, 2021, in connection with Canadian patent application No. 3,106,934, 4 pages. [cited by applicant]
Knowing your mix is completely homogeneous and air free, Intertronics presentation, Nov. 3, 2011 (35 pages). [cited by applicant]
S. Barbosa et al. “Physical-chemical properties of furosemide nanocrystals developed using rotation revolution mixer,” Pharm. Dev. Technol., vol. 21, No. 7, pp. 812-822, Aug. 31, 2015. [cited by applicant]
Kate Douglass et al., “Requirements and Best Practices for Sanitizing Engineering Controls,” Pharmacy Purchasing & Products, Sep. 2013, pp. 16-22 (5 pages). [cited by applicant]
Planetary Centrifugal Mixer ARE 310 & Planetary Centrifugal Vacuum Mixer ARV 310; Youtube video; https://www.youtube.com/watch?v=MudA4yDGtll&pp=ygVQUGxhbmV0YXJ5IENIbnRyaWZ1Z2FsIE1peGVyIEFSRSAzMTAgJiBQbGFuZXRhcnkgQ2VudHJ… [cited by applicant]
Department of Health, Board of Pharmacy, Compounding Rules Committee, Feb. 10, 2014 (5 pages). [cited by applicant]
Planetary Centrifugal Vacuum Mixer [ARV-310] | Thinky Corporation; Youtube video; https://www.youtube.com/watch?v=QVHJzTRQLok; (1 page), 2014. [cited by applicant]
Thinky mixer—Thinky Corporation; Youtube video; https://www.youtube.com/watch?v=jtiVIP9Bm2I; (1 page) 2014. [cited by applicant]